Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes

被引:131
作者
Sijts, AJAM
Ruppert, T
Rehermann, B
Schmidt, M
Koszinowski, U
Kloetzel, PM
机构
[1] Humboldt Univ, Charite, Inst Biochem, D-10117 Berlin, Germany
[2] Max Von Pettenkofer Inst, D-80336 Munich, Germany
[3] NIDDKD, Liver Dis Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA
关键词
antigen processing; LMP7T1A; hepatitis B virus; immunoproteasome; MHC class I;
D O I
10.1084/jem.191.3.503
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interferon (IFN)-gamma-induced cells express the proteasome subunits low molecular weight protein (LMP)2, LMP7, and MECL-1 (multicatalytic endopeptidase complex-like 1), leading to the formation of immunoproteasomes. Although these subunits are thought to optimize MHC class I antigen processing, the extent of their role and the mechanistic aspects involved remain unclear. Herein, we study the proteolytic generation of an human histocompatibility leukocyte antigen (HLA)-Aw68-restricted hepatitis B virus core antigen (HBcAg) cytotoxic T lymphocyte (CTL) epitope that is recognized by peripheral blood lymphocytes from patients with acute self-limited but not chronic hepatitis B virus (HBV). Immunological data suggest that IFN-gamma-induced rather than uninduced HeLa cells process and present the HBV CTL epitope upon infection with HBcAg-expressing vaccinia viruses. Analyses of 20S proteasome digests of. synthetic polypeptides coveting the antigenic HBcAg peptide demonstrate that only immunoproteasomes efficiently perform the cleavages needed for the liberation of this HBV CTL epitope. Although the concerted presence of the three immunosubunits appears essential, we find that both catalytically active LMP7 and inactive LMP7 T1A support CTL epitope generation. We conclude that LMP7 influences the structural features of 20S proteasomes, thereby enhancing the activity of the LMP2 and MECL-1 catalytic sites, which provide cleavage specificity. Thus, LMP7 incorporation is of greater functional importance for the generation of an HBV CTL epitope than cleavage specificity.
引用
收藏
页码:503 / 513
页数:11
相关论文
共 55 条
[41]   IDENTIFICATION OF HUMAN CANCERS DEFICIENT IN ANTIGEN PROCESSING [J].
RESTIFO, NP ;
ESQUIVEL, F ;
KAWAKAMI, Y ;
YEWDELL, JW ;
MULE, JJ ;
ROSENBERG, SA ;
BENNINK, JR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :265-272
[42]   INHIBITORS OF THE PROTEASOME BLOCK THE DEGRADATION OF MOST CELL-PROTEINS AND THE GENERATION OF PEPTIDES PRESENTED ON MHC CLASS-I MOLECULES [J].
ROCK, KL ;
GRAMM, C ;
ROTHSTEIN, L ;
CLARK, K ;
STEIN, R ;
DICK, L ;
HWANG, D ;
GOLDBERG, AL .
CELL, 1994, 78 (05) :761-771
[43]   IMPAIRED ASSEMBLY AND TRANSPORT OF HLA-A AND HLA-B ANTIGENS IN A MUTANT TXB CELL HYBRID [J].
SALTER, RD ;
CRESSWELL, P .
EMBO JOURNAL, 1986, 5 (05) :943-949
[44]   Mutational analysis of subunit iβ2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes [J].
Salzmann, U ;
Kral, S ;
Braun, B ;
Standera, S ;
Schmidt, M ;
Kloetzel, PM ;
Sijts, A .
FEBS LETTERS, 1999, 454 (1-2) :11-15
[45]   Sequence information within proteasomal prosequences mediates efficient integration of β-subunits into the 20 S proteasome complex [J].
Schmidt, M ;
Zantopf, D ;
Kraft, R ;
Kostka, S ;
Preissner, R ;
Kloetzel, PM .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 288 (01) :117-128
[46]   Inactivation of a defined active site in the mouse 20S proteasome complex enhances major histocompatibility complex class I antigen presentation of a murine cytomegalovirus protein [J].
Schmidtke, G ;
Eggers, M ;
Ruppert, T ;
Groettrup, M ;
Koszinowski, UH ;
Kloetzel, PM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (10) :1641-1646
[47]   Analysis of mammalian 20S proteasome biogenesis: The maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis [J].
Schmidtke, G ;
Kraft, R ;
Kostka, S ;
Henklein, P ;
Frommel, C ;
Lowe, J ;
Huber, R ;
Kloetzel, PM ;
Schmidt, M .
EMBO JOURNAL, 1996, 15 (24) :6887-6898
[48]  
Seliger B, 1996, CANCER RES, V56, P1756
[49]  
Sijts AJAM, 1996, J IMMUNOL, V156, P1497
[50]  
Tanaka K, 1997, ADV IMMUNOL, V64, P1, DOI 10.1016/S0065-2776(08)60885-8